BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada.
As previously announced, on August 19, 2024, Sonoma entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States, to be sold through hospital systems and other healthcare channels. The new amendment allows the same distributor to also distribute these products in Canada, and adds over-the-counter wound care products for sale in both countries.
“This expanded partnership with a global healthcare distributor will enable us to bring our wound care products and the regenerative power of Microcyn technology to Canada,” said Amy Trombly, CEO of Sonoma. “Our distributor’s expertise and distribution network will allow new patients in Canada the opportunity to benefit from improved management of both acute and chronic wounds, reduction in pain, itch and scarring, and the peace of mind that results from Sonoma’s safe and effective technology. We are also pleased that our distributor plans to sell over-the-counter products as well, allowing consumers to benefit from greater accessibility of our wound care products.”
Further information about the amendment can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on October 22, 2024.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
